Learn how you can manage and alleviate your current side effects while actively working to prevent a relapse or secondary cancer using evidence-based, non-toxic therapies.
Click the orange button to the right to learn more.
Human papillomavirus (HPV) increases the risk of many cancers including, according to the studies below, oropharyngeal cancer (OPC), a type of head and neck cancer.
If you have been diagnosed with head and neck cancer your oncologist will recommend those therapies that should give you the best chances of overall survival. What he or she may not talk about is if you have Human papillomavirus, if HPV caused your cancer in the first place and if clearing your Human papillomavirus may reduce your risk of head and neck cancer relapse.
I mention all the above because I developed a blood cancer called multiple myeloma while at the same time having HPV. While I will never know if HPV caused my multiple myeloma I do know that HPV increases the risk of MM.
I supplemented with AHCC for several months in 2010 and have cleared my HPV. I have remained in complete remission from MM, a supposedly “incurable” form of blood cancer, since I achieved complete remission in early 1999.
I am both a cancer survivor and cancer coach. I follow an evidence-based, non-toxic lifestyle including anti-cancer nutrition, supplementation, bone health, mind-body and lifestyle therapies.
Have you been diagnosed with oropharyngeal cancer? Have you been diagnosed with HPV? Please scroll down the page, post a question or comment and I will reply to you ASAP.
“A Japanese mushroom extract appears to be effective for the eradication of human papillomavirus (HPV), according to a pilot clinical trial. Ten HPV-positive women were treated orally with the extract, AHCC (active hexose correlated compound) once daily for up to six months. Five achieved a negative HPV test result — three with confirmed eradication after stopping AHCC — with the remaining two responders continuing on the study…”
“Human papillomavirus (HPV)-positive oropharyngeal cancer (OPC) also known as HPV16+ oropharyngeal cancer or HPV+ OPC is a recognized subtype of Oropharyngeal squamous cell carcinomas (OSCC), associated with the HPV type 16 virus.”
“Tumor HPV status is strongly associated with positive therapeutic response and survival compared with HPV-negative OPC. A possible explanation is “the lower probability of occurrence of 11q13 gene amplification, which is considered to be a factor underlying faster and more frequent recurrence of the disease” Presence of TP53 mutations, a marker for HPV- OPC, is associated with worse prognosis.
High grade of p16 staining is thought to be better than HPV PCR analysis in predicting radiotherapy response.“
“The longstanding notion that head and neck squamous cell carcinoma (HNSCC) is a uniform disease process is changing. Divergence in epidemiologic trends among HNSCCs arising in different anatomic subsites has introduced a view that HNSCC is a heterogeneous group. Analysis of molecular genetic changes discloses not just individual tumor differences, but also consistent large-scale differences that permit the recognition of important tumor subtypes. One recently recognized subtype is the human papillomavirus (HPV)-positive oropharyngeal carcinoma. HPV-positive oropharyngeal cancer now dominates the head and neck oncology landscape, and its escalating incidence is impacting on diagnostic, preventive and therapeutic practices…
HPV, particulary type 16, is detected in about 70% of oropharyngeal carcinomas. These HPV-positive cancers are increasingly recognized as a distinct subgroup of HNSCC with a biological and clinical profile that diverges from that of their HPV-negative counterparts..